Intelligent bio solutions inc. advances on fda 510(k) pathway with biocompatibility study success

New york, july 18, 2024 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of biocompatibility testing of its intelligent fingerprinting drug screening system, a pivotal phase in the clinical study plan required for fda 510(k) regulatory clearance.
INBS Ratings Summary
INBS Quant Ranking